PRGO: Symmetrical Triangle detected on 1 Jun 2026

PRGO is forming a symmetrical triangle in an established recovery from a rounding bottom pattern initiated in September 2025. The structure score of 15/15 indicates textbook triangle geometry with key support at $10.58 and resistance at $10.84, with current price at $11.05 trading above the midpoint. The breakout score of 10/13 suggests modest directional confirmation, while volume at 2.35M shares (0.91x average) reflects below-average participation. Overall score of 75/98 and 65.46% win probability indicate a solid but not exceptional setup. MACD histogram positive at 0.0168 supports upside bias.

Perrigo reported Q1 2026 results on May 6, 2026, announcing financial performance from continuing operations for the quarter ended March 28, 2026. Management highlighted progress in executing its transformation strategy, with positive momentum in U.S. Store Brand and Women's Health categories under a new category-led operating model. However, analyst confidence deteriorated substantially, with consensus EPS estimates drifting down 6.1% from $0.33. The earnings decline reflects margin compression, potentially driven by loss of exclusivity on higher-margin products and increased generic competition. The company expects to close a €327 million sale of its Dermacosmetics business in Q2 2026, which could provide near-term cash but masks underlying operational headwinds.

A breakout above $10.84 resistance would target the conservative estimate of $11.55, representing a 6.5% measured move from the triangle apex. Volume confirmation will be critical—expect breakout volume should exceed the 2.58M 20-day average given current 0.91x ratio. The pattern invalidates decisively below the key support level of $10.58, which represents a 4.2% downside risk. With 65.46% historical win probability, this pattern suggests slightly better-than-even odds of upside follow-through, though elevated volatility (48.27% 20-day, beta 1.92) increases the range of potential outcomes.

Recent estimate cuts signal deteriorating analyst sentiment, and the pattern coincides with a challenging operating environment for the company. Perrigo trades 57.79% below its 52-week high and is down 12.23% over the past three months, indicating persistent negative sentiment. The stock's high beta of 1.92 amplifies sector volatility—while healthcare sector regime is bullish (0.71 score), broad market swings could overwhelm technicals. RSI at 51.91 is neutral, but margin pressures noted in analyst commentary suggest earnings surprises remain tilted to downside. Volume participation below average during pattern formation raises breakout execution risk. The Dermacosmetics divestiture, while strategically positive, may distract management focus near-term.